Online Education

24HT00096 – A School Nurse’s Guide to Bleeding Disorders: Hemophilia

June 7, 2024

5:00 PM Eastern, June 8, 2026
The estimated time to complete this activity is 45 minutes.

This activity aims to enable the learner to enhance his/her knowledge about hemophilia, common treatment methods/products, and accommodations recommended to provide a safe and positive learning environment for the student with hemophilia.

A School Nurse’s Guide to Bleeding Disorders: Hemophilia contains information about hemophilia, its treatment, and accommodations that must be made in order to promote a safe and positive learning environment for the student with hemophilia. This includes a definition of hemophilia and a description of common symptoms; description of hemophilia treatment; and exploration of the Hemophilia Treatment Center (HTC) comprehensive care team as an essential resource in managing the student with hemophilia.

This accredited continuing education activity is designed for professional school nurses in schools attended by a child with hemophilia; teachers, physical education instructors, school administrators, and guidance counselors; other educators and healthcare professionals who require an introduction to school-related considerations for students with hemophilia.

At the conclusion of this activity, the participants should be better able to:

• State common misconceptions about hemophilia 
• Recall basic information about the etiology, inheritance, and severity of hemophilia 
• Identify prevalent locations and symptoms of joint and muscle bleeding in hemophilia 
• Describe hemophilia treatment strategies and medications utilized and avoided in hemophilia management 
• Interpret guidelines for participation in physical activity and sports by persons with hemophilia 
• Translate reasonable accommodations in the school setting to promote a safe and positive learning environment for the student with hemophilia 
• Explain the role of the Hemophilia Treatment Center as a resource for support for schools attended by a student with hemophilia 

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

The Partners in Bleeding Disorders Education Program is supported by educational grants from Genentech, a member of the Roche Group; Takeda Pharmaceuticals U.S.A., Inc.; and Novo Nordisk.

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

23HT00148 – A School Nurse’s Guide to Bleeding Disorders: von Willebrand Disease 

December 27, 2023 

5:00 PM Eastern, December 29, 2025
The estimated time to complete this enduring material is 30 minutes.

This activity aims to enable the learner to enhance his/her knowledge about von Willebrand disease (VWD), common treatment methods/products, and accommodations recommended to provide a safe and positive learning environment for the student with VWD.

A School Nurse’s Guide to Bleeding Disorders: von Willebrand Disease contains information about von Willebrand disease (VWD), its treatment, and accommodations that must be made in order to promote a safe and positive learning environment for the student with VWD. This includes a definition of VWD and a description of common symptoms; description of VWD treatment; and exploration of the Hemophilia Treatment Center (HTC) comprehensive care team as an essential resource in managing the student with VWD.

This accredited education activity is designed for professional school nurses in schools. Other care team members may find this education helpful including teachers, PE teachers, school administrators, and guidance counselors, other educators, and other health care professionals.

At the conclusion of this activity, the participants should be better able to:

• Apply basic information related to the etiology and symptoms of von Willebrand disease (VWD) to clinical practice with students
• Recognize common treatments utilized for VWD within the school setting
• Integrate strategies in the school setting to promote a safe and positive learning environment

In order to receive continuing education credit, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

An Overview of the Background, Inheritance and Pathophysiology of von Willebrand Disease

October 24, 2022
The estimated time to complete this activity is 45 minutes.

The purpose of this online learning activity is to enable the learner to develop an understanding of von Willebrand disease (VWD) by examining the discovery and evolution of scientific knowledge about VWD; genetic inheritance of the bleeding disorder; production, structure, and functions of von Willebrand factor (VWF); and characteristics of the different types of VWD.

• Review the history of von Willebrand Disease (VWD), including its discovery and evolution of scientific understanding of the bleeding disorder
• Discuss the epidemiology, inheritance, and diagnosis of VWD
• Examine the production, structure, and functions of von Willebrand factor (VWF)
• Differentiate the types and subtypes of VWD, including types 1, 2, and 3

This enduring material is intended for nurses and other healthcare professionals employed within the federally recognized U.S. hemophilia treatment center network (USHTCN) seeking training on von Willebrand disease (VWD) relating to the history and evolution of our understanding of the condition, the role of von Willebrand factor (VWF), and the differentiation of the multiple classifications of VWD.

This online learning activity provides an outline of the history, inheritance, and pathophysiology of von Willebrand Disease (VWD). It includes a description of how VWD was discovered and traces the evolution of knowledge about the bleeding disorder. It also details the genetic inheritance of VWD and the likelihood that offspring of an affected parent will be born with VWD. The activity examines the production and many functions of von Willebrand factor, described as “the Jedi knight of the bloodstream.” Finally, the activity differentiates the types of VWD on the basis of laboratory features. VWF function, VWF multimer quantity and quality, and symptoms.

• Roshni Kulkarni, MD
• Usha M. Reddy, MD
• Bruce L. Evatt, MD
• Connie H. Miller, PhD

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser (current version) – Firefox, Safari, Chrome, or Edge 
  • Cookies and JavaScript must be enabled in the browser

Gene Therapy for Providers 101

July 01, 2022

The estimated time to complete this activity is 45 minutes.

The purpose of this activity is to enable learners to develop basic knowledge of gene therapy for hemophilia, thereby enhancing learner competence to discuss gene therapy with patients who may benefit from this emerging treatment.

This learning activity provides basic education on hemophilia gene therapy, including the aims of gene therapy; the packaging, delivery, and activity of the replacement genes; and the means by which the replacement genes lead to production and/or availability of normal clotting factor in persons with hemophilia. The module will also review information that may be particularly important when discussing hemophilia gene therapy with patients, such as knowledgeable informed consent, outcomes data, and potential risks and benefits.

This enduring material is intended for multidisciplinary providers at hemophilia treatment centers, including nurses, physicians, pharmacists, physical therapists, social workers, and genetic counselors providing care to persons with hemophilia A and hemophilia B.

At the conclusion of this enduring material, the participants should be better able to:

• Describe a pathway to preparedness for gene therapy from education of the multidisciplinary healthcare team to clinical delivery
• Provide an overview of the goal of gene therapy for hemophilia
• Explain the elements of gene therapy (i.e. packaging, administration, mechanism of action)
• Define the profile of gene therapy candidates with FVIII deficiency and FIX deficiency
• Review known adverse effects from completed and ongoing clinical trials
• Articulate critical considerations for the multidisciplinary healthcare team in providing care for patients receiving gene therapy
• Discuss issues related to obtaining knowledgeable informed consent and counseling patients

• Steven Pipe, MD
• Shelley Crary, MD, MSCS

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

Gene Therapy for Providers 201

July 01, 2022

The estimated time to complete this activity is 60 minutes.

The purpose of this activity is to enable HTC multidisciplinary staff and institutional stakeholders to gain knowledge on the steps necessary to prepare an institution to administer AAV-mediated gene therapy for hemophilia.

This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.

This enduring material is intended for HTC multidisciplinary staff (physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, geneticists, genetic counselors, infusion room staff) and institutional stakeholders (e.g., HTC administrators and directors, clinic and pharmacy billing staff, insurance coordinators).

At the conclusion of this enduring material, the participants should be better able to:

• Identify patients who are eligible for AAV-mediated gene therapy
• Discuss key concepts involving education and shared decision-making for gene therapy
• Identify logistical/infrastructure requirements to procure, reconstitute and administer gene therapy at a dosing site
• Articulate the regional approach of preparing for gene therapy administration
• Distinguish the roles and responsibilities within the HTC team involved in the safety and efficacy assessments during short-and long-term monitoring before and after gene therapy
• Describe approaches to prevention, diagnosis, and treatment of vector-induced transaminitis after gene therapy

• Rebecca Kruse-Jarres, MD, MPH
• Ulrike Margret Reiss, MD
• Courtney Dawn Thornburg, MD, MS

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

Gene Therapy for Providers 301

July 01, 2022

The estimated time to complete this activity is 60 minutes.

The purpose of this activity is to enable HTC multidisciplinary staff and hospital staff to support patients and their families as they consider hemophilia gene therapy, including education of patients and families on basic concepts in hemophilia gene therapy; administrative preparedness for providers; and short- and long-term care demands.

This learning activity is a process-oriented intermediate course that will guide HTC staff through the steps an institution must take to prepare to administer hemophilia gene therapy upon commercial availability of these products.

This enduring material is intended for physicians, physician assistants, nurses, nurse practitioners, physical therapists, social workers, pharmacists, and infusion room staff.

At the conclusion of this enduring material, the participants should be better able to:

• Discuss introductory concepts in hemophilia gene therapy
• Outline the process of preparing patients, hemophilia treatment centers, and hospital systems for the administration of gene therapy
• Explain the steps necessary for multidisciplinary team members to engage in shared patient-centered and population focused problem solving when procuring a hemophilia gene therapy product, preparing the product, and infusing the patient safely
• Discuss short term monitoring, specifically immediately after infusion and during the first three months of follow up
• Discuss long term monitoring, specifically from 3 to 24 months post infusion and > 24 months post infusion

• Doris V. Quon, MD
• Lindsey A. George, MD

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

Hemophilia in Pictures

2005

The purpose of Hemophilia in Pictures is to provide basic knowledge about hemophilia through pictures and easy-to-understand information.

This online learning module covers a range of topics, including an introduction to hemophilia, assessing and managing bleeds, treatment of bleeds, staying healthy and preventing bleeds, and venipuncture and home therapy.

Hemophilia in Pictures is for hemophilia educators and people with hemophilia alike. The information is basic and is provided through pictures and easy-to-understand language, so it is accessible to anyone.

Hemophilia in Pictures has many goals. Please refer to the HIP Educators Guide to learn more about the educational goals for Educators as well as People with Hemophilia.

• Lara Oyesiku, Chair of the HIP Working Group and Nurse's Committee, England
• Martin Bedford, Educational Advisor, England
• Annie Gillham, Nurse Advisor, South Africa
• Dr. Peter Jones, Medical Advisor, England
• Kathy Mulder, Physiotherapy Advisor, Canada
• David Page, Educational Advisor, Canada
• Laurie Blackstock, WFH Education Officer

Upon launching the presentation, there are three handouts available for you to print or save for future reference: Educator Guide, Educator Glossary, and On Screen Notes.
To access the handouts, click on the slide notes and resources.

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

24HT62125 – Hereditary Hemorrhagic Telangiectasia: Right Under Your Nose

June 27, 2024

5:00 PM Eastern, June 26, 2026
The estimated time to complete this activity is 30 minutes.

This online learning activity aims to enable the learner to gain knowledge and expertise regarding hereditary hemorrhagic telangiectasia (HHT), including inheritance and pathophysiology, screening guidelines, management, and the importance of the multidisciplinary approach in caring for these patients. 

This online learning activity provides a detailed introduction to hereditary hemorrhagic telangiectasia (HHT) appropriate for an audience of multidisciplinary health care providers involved in the team-based care of patients with HHT. This overview includes information on the genetic inheritance and pathophysiology of HHT as well as the widely-used Curaçao diagnostic criteria to determine if a person has HHT, consensus screening guidelines for HHT management, and an explanation of the importance of a multidisciplinary approach to care of patients with HHT. This activity incorporates case scenarios and interactive questions to encourage active learning through application of the content. 

This accredited continuing education activity is designed for physicians, physician assistants, nurse practitioners, nurses, and other multidisciplinary team members who care for patients with hereditary hemorrhagic telangiectasia. 

At the conclusion of this activity, the participants should be better able to:

• Identify the Curaçao criteria for determining the likelihood of Hereditary Hemorrhagic Telangiectasia (HHT) in an undiagnosed individual 
• Describe HHT genetics and pathophysiology 
• Discuss the international consensus screening guidelines for HHT management 
• Recall management of epistaxis, iron deficiency, and pulmonary arteriovenous malformations (PAVSMs) in HHT 
• Explain the importance of an HHT Center-driven multidisciplinary approach in caring for patients with HHT 

• Manjusha Kumar, MD
• Magdalena Lewandowska, MD

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Indiana Hemophilia & Thrombosis Center. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIANS/PHYSICIAN ASSISTANTS
The University of Nebraska Medical Center designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.5 ANCC contact hour(s). Nurses should only claim credit for the actual time spent participating in the activity.

No commercial support was received for this activity.

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

How Does Blood Clot?

The purpose of this activity is to enable the learner to improve understanding of and increase interest in the basic concepts involved in the complex coagulation process to ultimately improve patient care.

• Examine the coagulation process from the point of injury to clot resolution.
• Evaluate the platelet reaction step of normal hemostasis.
• Differentiate among the three coagulation pathways, including the various clotting factors that participate in hemostasis.

Nurses and other healthcare staff employed within or affiliated with the U.S. Hemophilia Treatment Center (HTC) network.

An animated module illustrating the coagulation cascade.

• Roshni Kulkarni, MD
• Usha M. Reddy, MD
• Bruce L. Evatt, MD

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High speed internet connection
• Any one Internet browser:
  • Firefox (Most Current Version)
  • Safari (Most Current Version)
  • Google Chrome (Most Current Version)
  • MS Internet Explorer (Most Current Version)
  • Cookies and JavaScript must be enabled in all browsers.
  • All browsers must have flash plug in installed and enabled.
• Cookies and JavaScript must be enabled in all browsers.
• All browsers must have flash plug in installed and enabled.
• Please note: This program requires FLASH PLAYER. If your computer does not have FLASH PLAYER, or does not allow such files to play, you will not be able to view this program. You will need to speak to your institution’s Information Technology department about enabling or installing FLASH PLAYER onto your computer.

23HT00125 – Physical Therapy and Comprehensive Care

December 1, 2023

5:00 PM Eastern, December 1, 2025
The estimated time to complete this activity is 45 minutes.

The purpose of this online learning module is to enable the learner to gain knowledge of the physical therapist’s role in providing comprehensive care at U.S. hemophilia treatment centers (HTCs), as well was the resources and opportunities available to physical therapists in the U.S. HTC Network.

The activity begins with a brief description of the U.S. hemophilia treatment center (HTC) network and the comprehensive care model utilized at these centers. It then introduces the Physical Therapy Working Group (PTWG) of the National Bleeding Disorders Foundation and resources available from this group, including recommendations on physical therapy evaluation elements as well as physical therapy treatment guidelines for bleeding disorder management. The activity also explains the physical therapist’s contribution to comprehensive care, including his or her role in helping patients select appropriate sports, physical activity, and employment.

This accredited continuing education activity is designed for physical therapists, physical therapy assistants, nurses, nurse practitioners, and other health care providers who are involved with the federally recognized U.S. Hemophilia Treatment Center, or HTC, network or otherwise engaged in comprehensive care and/or physical therapy management of individuals with hemophilia and other bleeding disorders.

This activity assumes that the learner possesses fundamental knowledge of the musculoskeletal and neurological systems and a basic understanding of bleeding disorders and the comprehensive care model. Learners who do not meet these criteria may wish to complete the PartnersPRN activity, “Understanding Hemophilia,” prior to completion of this module on physical therapy and comprehensive care.

At the conclusion of this activity, the participants should be better able to:

• Discuss the history of the U.S. Hemophilia Treatment Center (HTC) network and the components of the multidisciplinary comprehensive care model employed by HTCs
• Explain the role of the Physical Therapy Working Group in the U.S. HTC network and resources available from this group
• Name funding opportunities available to physical therapists working in the U.S. HTC network
• Recognize physical therapy as a key discipline in the multidisciplinary comprehensive care of people with bleeding disorders
• Identify Physical Therapy Working Group guidelines for the management of bleeding disorders and the essential components of various team members’ roles within the comprehensive clinic as prescribed by the Physical Therapy Working Group
• State the importance of sports and physical activity for persons with bleeding disorders and the physical therapist’s role in helping patients select appropriate activities
• Describe vocational considerations often discussed between the physical therapist and patient when treating persons with bleeding disorders

• Stacie Akins, PT, MHS
• Sherry Herman-Hilker, PT, MS
• Jennifer Newman, PT, MSPT

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 0.75 ANCC contact hour(s). Nurses should only claim credit for the actual time spent participating in the activity.

IPCE CREDIT
This activity was planned by and for the healthcare team, and learners will receive 0.75 Interprofessional Continuing Education (IPCE) credit for learning and change.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
Internet browser (current version) - Firefox, Safari, Chrome, or Explorer
• Cookies and JavaScript must be enabled in the browser

23HT00124 – Physical Therapy in the Care of Persons with Bleeding Disorders

December 1, 2023

5:00 PM Eastern, December 1, 2025
The estimated time to complete this activity is 90 minutes.

The purpose of this online learning module is to enable the learner to increase their knowledge on the musculoskeletal concerns, potential complications, and physical therapy management of bleeding disorders.

After providing a review of basic information about hemophilia and von Willebrand disease, this learning module describes signs and symptoms of hemophilic bleeding, the complications associated with recurrent bleeding, physical therapy interventions for acute and chronic musculoskeletal complications of hemophilia, and imaging techniques including X-ray, MRI, and musculoskeletal ultrasound, which may be used to assess musculoskeletal status in patients with bleeding disorders. 

This accredited continuing education activity is designed for physical therapists, physical therapist assistants, nurses, nurse practitioners, and other health care providers who are involved with the federally recognized U.S. Hemophilia Treatment Center, or HTC, network or otherwise engaged in comprehensive care and/or physical therapy management of individuals with hemophilia and other bleeding disorders.

This activity assumes that the learner possesses fundamental knowledge of the musculoskeletal and neurological systems and a basic understanding of bleeding disorders and the comprehensive care model. Learners who do not meet these criteria may wish to complete the PartnersPRN activity, “Understanding Hemophilia,” prior to completion of this module on physical therapy and comprehensive care.

At the conclusion of this activity, the participants should be better able to:

• Summarize basic information on the clinical picture of hemophilia and von Willebrand disease
• Identify signs and symptoms of acute and chronic musculoskeletal bleeding including hemarthroses and muscle bleeding
• Recognize the complications of recurrent hemarthroses including chronic synovitis, cartilage destruction, and hemophilic arthropathy
• Discuss physical therapy interventions for acute bleeding events and chronic musculoskeletal complications of bleeding disorders and how the multidisciplinary team can help implement these strategies to improve patient outcomes
• Recall imaging techniques and their use to assess musculoskeletal status in patients with bleeding disorders

• Stacie Akins, PT, MHS
• Sherry Herman-Hilker, PT, MS
• Jennifer Newman, PT, MSPT

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 70% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.5 ANCC contact hour(s). Nurses should only claim credit for the actual time spent participating in the activity.

IPCE CREDIT
This activity was planned by and for the healthcare team, and learners will receive 1.5 Interprofessional Continuing Education (IPCE) credit for learning and change.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
Internet browser (current version) - Firefox, Safari, Chrome, or Explorer
• Cookies and JavaScript must be enabled in the browser

September 15, 2023

5:00 PM Eastern, September 15, 2025 
The estimated time to complete this activity is 60 minutes.

The purpose of this activity is to enable the learner to address the burden of reduced quality of life that has been documented among persons and families with hemophilia with an inhibitor. This module describes various validated quality of life instruments and patient testimonials to provide insight into differences in both the physical and mental health-related quality of life domains for persons with hemophilia with an inhibitor and their parents/caregivers versus persons with hemophilia without an inhibitor. Highlighting how living with an inhibitor compromises quality of life, the module offers strategies for effective psychosocial interventions to address these issues in persons with hemophilia with an inhibitor and their caregivers and family members. Social workers, nurses, and other healthcare professionals involved in the management of persons with hemophilia with an inhibitor will benefit by learning more about interventions to address reduced quality of life and how to implement such strategies. 

The module reviews studies using a variety of validated quality of life instruments to provide insight into differences in both the physical and mental health domains for persons with hemophilia with an inhibitor and their parents/caregivers versus persons with hemophilia without an inhibitor. The module also discusses the differences in health-related quality of life among persons with an inhibitor based on treatment frequency, age, and adherence. It also covers the impact of inhibitors on quality of life of parents/caregivers of persons with hemophilia with an inhibitor, describes a real-time study of health-related quality of life differences on bleed vs nonbleed days, and describes the effect of prophylaxis on persons with an inhibitor. The module concludes with an overview of various strategies to psychosocial interventions in persons with an inhibitor. 

This accredited continuing education activity is designed for psychosocial professionals, nurses, nurse practitioners, and other members of the health care team who are involved in the care of individuals with congenital hemophilia who have an inhibitor to clotting factor VIII or IX. 

At the conclusion of this activity, the participants should be better able to:

• Explain the basic pathophysiology of an inhibitor in hemophilia 
• Describe the psychosocial, physical, and financial impact of an inhibitor in persons with hemophilia and their families 
• Recount differences in physical and mental health-related quality of life domains for persons with hemophilia with an inhibitor versus persons with hemophilia without an inhibitor.
• Identify differences in quality of life for parents/caregivers of persons with hemophilia with an inhibitor versus parents/caregivers of persons with hemophilia without an inhibitor 
• Compare differences in quality of life among persons with hemophilia with an inhibitor on bleed and nonbleed days 
• Describe differences in quality of life for the physical and psychosocial domains for persons with hemophilia with an inhibitor on prophylaxis versus those receiving on-demand treatment 
• Discuss the roles/responsibilities of the healthcare team when utilizing psychosocial interventions and other communication techniques when caring for persons with hemophilia with an inhibitor 

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 80% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.0 clinical continuing education credits. The content level of this activity is advanced.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.  

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

August 29, 2023

5:00 PM Eastern, August 29, 2025 
The estimated time to complete this activity is 75 minutes.

The purpose of this activity is to enable learners to provide competent psychosocial support to persons with hemophilia (PWH) as they navigate changes associated with the aging process. 

This activity will describe the increasing burden of chronic disease in elderly Americans and the role of extended life expectancy on prevalence of chronic conditions among elderly persons with hemophilia. The activity assesses psychosocial considerations in managing care for elderly persons with hemophilia and recommends practical assessment strategies for use in the Hemophilia Treatment Center environment to optimize care of these individuals. 

This accredited continuing education activity is designed for social workers, nurses, and other members of the multidisciplinary comprehensive care team at U.S. federally-recognized hemophilia treatment centers (HTCs) who routinely encounter adult persons with hemophilia (PWH) in need of support to navigate changes associated with the aging process.

At the conclusion of this activity, the participants should be better able to:

• Describe the increasing burden of chronic disease among persons aged 65 and over in the United States 
• Review the evolution of hemophilia treatment and the associated increase in life expectancy among persons with hemophilia 
• Evaluate the prevalence of chronic conditions among aging and elderly persons with hemophilia 
• Assess psychosocial considerations pertinent to the care of aging and elderly persons with hemophilia 
• Incorporate practical psychosocial assessment strategies in the hemophilia treatment center environment to optimize care of aging and elderly persons with hemophilia 

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity
• Complete the evaluation
• Complete the post-test with a score of 80% or better
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS
The University of Nebraska Medical Center designates this activity for 1.25 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 1.25 clinical continuing. The content level of this activity is advanced.

Supported by an educational grant from Takeda Pharmaceuticals U.S.A., Inc.  

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

The Role of the Nurse in Hemophilia Care

The purpose of this module is to familiarize the learner with the critical role nurses play worldwide in the multidisciplinary care team.

• Examine the critical and variable role of the nurse in the care of people with hemophilia.
• Review the role responsibilities of the nurse related to education, care delivery, coordination of the healthcare team, and support of patient and family to learn to live with hemophilia.

While there are some responsibilities that are universal for all nurses, there is also a great deal of variation in the role and responsibilities of nurses in hemophilia care. This learning module describes those roles and responsibilities and some of the variation that may occur throughout the world.

• World Federation of Hemophilia

June 18, 2013

This module was created to describe the worldwide variation in the role and responsibilities of nurses in hemophilia care.

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser

24HT00086 – Understanding Hemophilia

July 15, 2024

5:00 PM Eastern, July 15, 2026 
The estimated time to complete this activity is 120 minutes.

"Understanding Hemophilia" is a 6-part online learning activity that aims to enable clinicians at U.S. Hemophilia Treatment Centers to gain knowledge and develop expertise on the pathogenesis, inheritance, symptoms, potential complications, and clinical management of hemophilia.

This 6-part online learning activity introduces basic concepts of hemophilia.

Part 1: Pathogenesis & Inheritance examines the coagulation system and processes, the deficit in hemophilia that interferes with clot formation, differences among types of hemophilia, and the sex-linked inheritance pattern of hemophilia.

Part 2: Symptoms & Sequelae distinguishes bleeding patterns and clinical presentation of hemophilia based on severity, differentiates types of bleeding episodes, and discusses physical/psychosocial sequelae of hemophilia.

Part 3: Factor Concentrates & Hemophilia Management discusses episodic and prophylactic management of hemophilia with clotting factor concentrate, different factor therapy protocols, and nursing considerations in administration of clotting factor concentrates.

Part 4: Introduction to Inhibitors explains the immune response and inhibitor development, signs/symptoms and risk factors of inhibitors, the impact of inhibitors on persons with hemophilia, inhibitor treatment strategies and challenges, and the positive health outcomes of immune tolerance induction therapy.

Part 5: Non-Factor Therapies covers gene therapy for hemophilia and the novel agent emicizumab. Gene therapy includes goals of therapy, delivery of gene therapy, eligibility criteria, patient readiness considerations pre- and post-therapy, and long-term follow-up post-therapy.

Part 6: Carrier Considerations reviews hemophilia sex-linked genetics and introduces recommendations for the management of carriers and women with hemophilia, neonatal diagnosis and circumcision in males with hemophilia, and key considerations of postpartum management of carriers and women with hemophilia.

This accredited continuing education activity is designed for physical therapists, nurses, nurse practitioners, social workers and other clinical and non-clinical staff at federally recognized U.S. Hemophilia Treatment Centers who wish to develop an understanding of basic concepts of hemophilia. This activity is particularly appropriate for clinicians within their first six months of employment at an HTC.

• Describe the pathogenesis and inheritance patterns concerning the different factor deficiencies in hemophilia including the symptoms and sequelae that may occur
• Discuss the target factor levels for situational bleeding episodes in conjunction with the appropriate factor replacement protocols, prophylactic treatments, and nursing considerations in administration of clotting factor concentrates
• Review the development and impact of inhibitors on persons with hemophilia, including signs and symptoms, risk factors, treatment implications, and nursing considerations
• Describe the goals of hemophilia gene therapy and describe the mechanism of action for hemophilia gene therapy
• Summarize the MASAC recommendations on the use of Emicizumab such as the indications, management approaches, and concurrent use with bypassing agents
• Articulate the role of genetic testing in the identification of potential carriers and women with hemophilia and the hemostatic management recommendations during pregnancy, labor and delivery, and the postpartum phases

• Jennifer Maahs, MSN, PNP
• Amy Shapiro, MD

In order to receive continuing education credits, you must complete these steps prior to the activity expiration date.

• Read the Disclosure Information found in the To Dos section.
• Complete the learning activity.
• Complete the evaluation.
• Complete the post-test with a score of 80% or better.
• Upon successful completion of the post-test your certificate of completion will be available to print or save

In support of improving patient care, this activity has been planned and implemented by University of Nebraska Medical Center and Partners in Bleeding Disorders Education Program. University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

NURSES/NURSE PRACTITIONERS

The University of Nebraska Medical Center designates this activity for 2.0 ANCC contact hour(s). This activity is provided for 0.3 contact hours related to pharmacotherapeutic content. Nurses should only claim credit for the actual time spent participating in the activity.

SOCIAL WORKERS

As a Jointly Accredited Organization, University of Nebraska Medical Center is approved to offer social work continuing education by the Association of Social Work Boards (ASWB) Approved Continuing Education (ACE) program. Organizations, not individual courses, are approved under this program. Regulatory boards are the final authority on courses accepted for continuing education credit. Social workers completing this course receive 2 clinical continuing education credits. The content level of this activity is beginner.

Partners in Bleeding Disorders Education Programs are currently supported by educational grants from Genentech, a member of the Roche Group; Takeda Pharmaceuticals U.S.A., Inc.; and Novo Nordisk.  

If you have any questions about this activity, please contact partners@inheme.org. For technical support please open a ticket in the Partners Support Center.

• 2 gigabytes of RAM
• High-speed internet connection
• Internet browser (current version) – Firefox, Safari, Chrome, or Edge
  • Cookies and JavaScript must be enabled in the browser